ADMA - ADMA Biologics Inc

ADMA - ADMA Biologics Inc

https://www.admabiologics.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Is Adma Biologics ( ADMA ) a Buy as Wall Street Analysts Look Optimistic?

Zacks Commentary • 5 days, 2 hours ago • score: 0.16

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum

Zacks Commentary • 1 month, 1 week ago • score: 0.27

ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.

Adma Biologics ( ADMA ) Q2 Earnings and Revenues Beat Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.17

Adma Biologics (ADMA) delivered earnings and revenue surprises of +7.14% and +0.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Is ADMA Biologics Gaining or Losing Market Support? - ADMA Biologics ( NASDAQ:ADMA )

Benzinga • 1 month, 2 weeks ago • score: 0.24

ADMA Biologics's ADMA short percent of float has fallen 10.9% since its last report. The company recently reported that it has 14.47 million shares sold short, which is 7.44% of all regular shares that are available for trading.

Adma Biologics ( ADMA ) Ascends While Market Falls: Some Facts to Note

Zacks Commentary • 1 month, 2 weeks ago • score: 0.36

In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day.

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

GlobeNewswire • 1 month, 2 weeks ago • score: 0.23

Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET ...

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 - ADMA Biologics ( NASDAQ:ADMA )

Benzinga • 1 month, 2 weeks ago • score: 0.24

RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 ( GLOBE NEWSWIRE ) -- ADMA Biologics, Inc.

Adma Biologics ( ADMA ) Rises As Market Takes a Dip: Key Facts

Zacks Commentary • 1 month, 2 weeks ago • score: 0.18

The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.

52W High

$25.67

52W Low

$13.50

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.53

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

18.54

Forward P/E (<15 better)

28.99

EV/EBITDA (<8 favorable)

23.94

EV/Revenue (<3 favorable)

8.23

P/S (TTM) (<3 favorable)

7.93

P/B (<3 favorable)

9.82

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.57%

Institutions (25–75% balanced)

90.75%

Shares Outstanding

238,631,000

Float

233,863,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

474,174,000

Gross Profit (TTM)

251,315,000

EPS (TTM)

0.85

Profit Margin (>10% good)

0.44%

Operating Margin (TTM) (higher better)

0.35%

ROE (TTM) (>15% strong)

0.71%

EPS YoY (Quarterly) (>10% good)

0.08

Revenue YoY (Quarterly) (>8% good)

0.14

Momentum

Bearish momentum

Value

-0.4974

Previous

-0.4841

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025